HCPCS Code J2506 | Description & Billing Guidelines

J2506 describes the drug pegfilgrastim and can be billed for 0.5 milligrams. Biosimilars are excluded. Pegfilgrastim is often administered by subcutaneous injection.

What Is J2506?

HCPCS code J2506 represents 0.5 mg of pegfilgrastim, excluding biosimilars, typically administered by subcutaneous injection to decrease the chances of infection in patients receiving chemotherapy.

The standard dosage of pegfilgrastim is six milligrams administered subcutaneously.  Pegfilgrastim may be supplied as a 6 mg/0.6 mL solution in a single–dose prefilled syringe. 

Providers may order pegfilgrastim, which helps the body make more white blood cells, to decrease the infection rate in patients receiving anti-cancer drugs linked to bone marrow suppression and febrile neutropenia. 

Neutropenia refers to a decreased number of neutrophils, the blood’s most abundant form of white blood cells. Neutrophils originate from stem cells in the bone marrow and are essential to the functioning of the immune system.

Description

J2506 is an HCPCS code, and the official description is written below.

Short Description: “Inj pegfilgrast ex bio 0.5mg.”

Long Description: “Injection, pegfilgrastim, excludes biosimilar, 0.5 mg.”

Pricing Indicator: 53

Code: O1E

Code Added: January 01, 2022

Last Changed: January 01, 2022

Billing Guidelines

Report HCPCS code J2506 for each 0.5 mg of pegfilgrastim. This code does apply to biosimilars, drugs that are biologically similar to or interchangeable with a Food and Drug Administration–approved biological product in terms of indications and effectiveness.

Report modifier JW if the dose of pegfilgrastim is only part of a vial and the remainder must be discarded.

Brand names for the drug Pegfilgrastim include Neulasta®.

Reference

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761075s000lbl.pdf